Skip to search formSkip to main contentSkip to account menu

Oxycodone measurement

Known as: OXYCDN, Oxycodone, Oxycontin 
The determination of the amount of oxycodone present in a sample.
National Institutes of Health

Related topics

Related topics

5 relations
CDISC SDTM Laboratory Test Terminology by CodeCDISC SDTM Laboratory Test Terminology by NameClinical Data Interchange Standards Consortium TerminologyOxycodone

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Use of an algorithm applied to urine drug screening to assess adherence to an oxycontin regimen.
OBJECTIVE This study examined the ability of an algorithm applied to urine drug levels of oxycodone in healthy adult volunteers… 
2018
2018
Correlations of cancer pain degree with levels of β-EP, CGRP and PGE2 and the effects of oxycontin on them.
PURPOSE To analyze the effects of Oxycontin on β-endorphin (β-EP), calcitonin gene-related peptide (CGRP) and prostaglandin E2… 
2018
2018
Standardized nursing and therapeutic effect of oxycontin on oral mucosal pain in nasopharyngeal carcinoma patients
Aim: This study aims to explore the standardized nursing and therapeutic effect of OxyContin on oral mucosal pain in… 
Review
2018
Review
2018
Incidence of nonmedical use of OxyContin and other prescription opioid pain relievers before and after the introduction of OxyContin with abuse deterrent properties
ABSTRACT Objectives: There is an epidemic of nonmedical and extra-medical use opioid abuse, addiction, and overdose. Extended… 
2018
2018
Abuse-deterrent properties of REMOXY® ER, a high-viscosity extended-release oxycodone formulation.
OBJECTIVE These in vitro studies compared abuse-deterrent properties of REMOXY ER (extended-release oxycodone), a novel, high… 
Review
2018
Review
2018
A nasal abuse potential randomized clinical trial of REMOXY® ER, a high-viscosity extended-release oxycodone formulation.
OBJECTIVE This study examined the nasal abuse deterrence of REMOXY ER, a novel high-viscosity extended-release oxycodone… 
2016
2016
(362) In vitro assessment of the effects of alcohol on the release rate of extended-release opioid formulations (Hysingla® ER, OxyContin® and Zohydro® ER).
2014
2014
Curative Effects and Costs of Oxycontin Combined with Bio-electric Stimulation Therapy in Treatment of Moderate or Severe Cancer Pain
Objective To investigate the curative effects,adverse reactions and costs of oxycodone hydrochloride tablets( Oxycontin) combined… 
Review
2007
Review
2007
An Exploratory Study of OxyContin Use Among Individuals with Substance Use Disorders
Abstract This study surveyed 422 individuals being treated in a substance abuse treatment program that offers various levels of… 
2001
2001
Steady-state pharmacokinetic comparison of a new, once-daily, extended-release morphine formulation (Morphelan™) and OxyContin® twice daily
Context. Morphelan2 (morphine sulfate extended release), a new, once-daily, oral morphine sulfate formulation, releases morphine… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)